• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Atomoxetine-associated hemospermia: a case report.
【24h】

Atomoxetine-associated hemospermia: a case report.

机译：阿托莫西汀相关性精子增多症：一例。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Sir: Atomoxetine is the only nonstimulant medication approved by the U.S. Food and Drug Administration for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults. Since its approval in 2002, it has been widely prescribed and has been associated with a low overall incidence of adverse effects. The 4 most common adverse effects include dry mouth, insomnia, nausea, and erectile dysfunction.1 The following case report describes a novel adverse effect associated with atomoxetine-hemospermia.Case report. Mr. A, a 24-year-old man, was first noted to have problems with inattention, impulsiveness, and hyperactivity at age 4. He was officially given a diagnosis of ADHD in first grade and was prescribed methylphenidate. The patient derived variable benefit from methylphenidate, a benefit that seemed to wane over time. When he had difficulty adjusting to higher doses (up to 20 mg twice daily), his parents elected to discontinue the medication altogether. Fortunately, the patient was able to compensate for his ADHD symptoms without pharmacotherapy, eventually graduating from college with a 3.4 grade point average.
机译：主席先生：Atomoxetine是美国食品药品监督管理局批准的唯一用于治疗儿童，青少年和成人的注意力不足/多动症（ADHD）的非兴奋剂。自2002年获得批准以来，它已被广泛开处方，并且与不良反应的总体发生率较低有关。四种最常见的不良反应包括口干，失眠，恶心和勃起功能障碍。1以下病例报告描述了与阿托西汀-血精症相关的新型不良反应。 A先生是24岁的男性，最初在4岁时出现注意力不集中，冲动和活动过度的问题。他被正式诊断为ADHD一年级，并被开具哌醋甲酯处方。患者从哌醋甲酯中获得了不同的收益，随着时间的流逝，这种收益似乎消失了。当他难以适应更高的剂量（每天两次，每次最多20 mg）时，他的父母选择完全停药。幸运的是，该患者无需进行药物治疗即可弥补其ADHD症状，最终以平均3.4分的成绩从大学毕业。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号